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Abstract
There have been multiple NOD2/CARD15 genotype-
phenotype analyses undertaken in patients with Crohn's 
disease since the gene’s discovery in 2001. This review 
focuses on the major published series based upon 
their size and on the presence of specific clinical and 
genetic information provided in the published material 
from 2001 to 2005. Twelve studies provided raw data 
to carry out comparisons of disease location while ten 
studies included analysis of NOD2/CARD15 genotypes. 
NOD2/CARD15 variant frequency in ileal disease did not 
differ significantly among studies, whereas a comparison 
of disease location demonstrated highly significant 
differences among studies. Meta-analysis confirmed 
signif icant associat ions between NOD2/CARD15 
variants and both ileal and ileocolonic disease locations, 
and with both stricturing and penetrating forms of 
disease behavior. This review underlines the significant 
phenotypic differences that exist among populations, 
including similar ethnic groups, and has demonstrated 
the need for further studies of patients with long-term 
“inflammatory” Crohn’s disease.
© 2006 The WJG Press. All rights reserved.
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INTRODUCTION
Chronic idiopathic inflammatory bowel diseases (IBD), 
made up predominantly of  Crohn’s disease (CD) and 
ulcerative colitis, remain fertile ground for both clinical and 
basic science research. These conditions have been held 
up as classic examples of  complex polygenic disorders 
with the working hypothesis of  a genetically susceptible 
host manifesting the disease phenotype after exposure to 
a single or a series of  environmental triggers. Study of  
the genetics of  IBD has expanded rapidly over the past 
10 years since publication of  the first genome-wide scan 
in 1996[1]. Technical advances have aided this advance 
with the culmination being the discovery of  the NOD2/
CARD15 gene within IBD1 on chromosome 16[2,3]. 
The case for further identification of  IBD susceptibility 
genes has been put forward, specifically regarding the 
organic cationic transporters, OCTN1 and OCTN2, on 
chromosome 5 (IBD5) and DLG5 on chromosome 10[4,5]. 
These genes have not received universal support from 
independent studies and remain topics for discussion and 
research, specifically including further functional studies.
These rapid advances in IBD genetics, fuelled by the 
interest and enthusiasm of  both clinicians and geneticists, 
has set the pace of  IBD research over the past 8-10 years, 
which has succeeded the “IBD immunology” era of  the 
1990’s. While the latter gave us a plethora of  cytokine data, 
including the important role of  TNF-a leading to anti-TNF 
strategies in CD, the discovery of  NOD2 highlighted the 
significance of  the gut’s innate immune system including 
pathogen-associated molecular patterns (PAMPs)[6]. This 
progress has been particularly challenging for clinician 
researchers as they are expected to translate these critical 
discoveries into meaningful changes and advances in 
clinical practice, including assessment and treatment of  
IBD patients. In this review, we will assess the clinical 
interpretations of  major breakthroughs in CD genetics 
focusing on the NOD2/CARD15 gene, including both the 
strengths and limitations of  such studies and an analysis of  
significant differences in phenotypes and genotypes, and we 
will offer suggestions for future studies[7,8].
ClassIfICaTION Of pheNOType
Cl in i ca l c l a s s i f i ca t ions o f  CD seem to be used 
synonymously with ter ms for phenotypes, and a 
number of  papers have described “genotype-phenotype 
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correlations”. However, genotypes and phenotypes are 
derived in fundamentally different ways. While genotype 
is based upon a limited number of  options that can be 
determined mechanically and thus objectively, derivation 
of  phenotype is subjective and influenced by potentially 
multiple variables, with many yet to be identified. A 
number of  variables may not be included in multivariate 
analysis when genotype-phenotype analyses are performed. 
The clinical classification systems that have been put 
forward have been purposefully kept simple. This may 
have been done to encourage individuals and groups 
to adopt them and hence maximize opportunities to 
compare and combine datasets[9-11]. However, given this 
intention, it does not appear to have been successful for 
genotype-phenotype studies in CD. The updated Vienna 
classification for Crohn’s disease, now known as the 
Montreal classification, has maintained a simple approach 
including age at diagnosis, location, and behavior as the 
major parameters, with perianal disease as a subgroup 
of  behavior[11]. It has appropriately split age at diagnosis 
and perianal penetrating from internal penetrating, 
but has not clarified the issue of  stricturing disease 
working independently of  penetrating disease[12]. There 
is no mention of  the need to demonstrate the presence 
of  transmural inflammation, assuming that this is a 
prerequisite for the diagnosis of  CD. This is relevant to 
subsequent study of  those patients with inflammatory CD 
who do not evolve into a stricturing and/or penetrating 
pattern. Do these patients fit into the definition of  CD, 
given that they do not appear to show any association with 
NOD2/CARD15 after correction for disease duration?[13] 
Other variables that may well influence natural history, 
including smoking, prior appendectomy, and body 
mass index, have thus far not been included in this 
classification[14-16]. The latter may influence development of  
penetrating disease, the level of  inflammation and hence 
CRP and the risk of  metabolic bone disease[17,18]. 
Clinical classification systems for ulcerative colitis 
are few. There was no such system included in the 
Vienna initiative. The Montreal paper presented a simple 
classification based upon distribution and activity, but both 
of  these parameters are subjective, particularly when the 
former is based upon macroscopic and not microscopic 
observations. There is again no inclusion of  smoking or 
prior appendectomy despite strong evidence supporting a 
role for appendectomy in (re)shaping the natural history 
of  ulcerative colitis.
No classification system or phenotypic approach 
has attempted to embrace the microscopic pattern 
of  inflammation, damage and repair seen in both CD 
and ulcerative colitis. Limited work has been done on 
granulomata and their association with both clinical 
outcomes and with some genetic polymorphisms[19-21]. 
This is in contrast to several other fields of  research, 
including liver disease, where histological appearances are 
used as important aids in determining the risk of  fibrosis, 
and colorectal cancer, in which significant heterogeneity 
has been identified among cancers based both upon 
histological appearances and molecular markers[22,23].
sTReNgThs aND lImITaTIONs Of
sTUDIes TO DaTe
Disease susceptibility and phenotype-genotype analyses 
have arrived in two “waves” since the seminal publications 
on NOD2/CARD15 and CD in 2001. The first wave 
of  papers identified the key CD-causing variants in this 
gene and went on to establish an association with ileal 
location[12,24-29]. Some studies in this group supported a 
stronger association with stricturing disease behavior and 
not ileal location, after multivariate analysis[12,24,29]. Two 
studies carried out haplotype analysis[27,28]. The second 
wave included studies from smaller centers, predominantly 
across Europe, focusing on phenotype-genotype 
correlations[30,40]. There have been a limited number of  
studies that have investigated response to therapy[41,42].
The limitations of  these studies center around two 
points: case-control ascertainment and phenotypic 
classification. Thus far, all of  these studies have been 
sourced from specialist-based cohorts and often from 
large, tertiary referral centers[12,24-29]. Ascertainment of  
cases has also been influenced by earlier genetic studies 
where the primary aim has been “gene discovery” and 
hence there have been an exaggerated number of  CD 
multiplex families[12,24]. Many of  the studies combine the 
resources of  multiple sites, which have contributed to 
collection of  these multiplex families[12,24,25]. The method 
of  ascertainment of  controls is not always clear, and in the 
majority of  cases they do not represent true population 
controls. Specifically, some studies have excluded controls 
with a family history of  IBD thus biasing the population 
even further.
Since the majority of  studies lack power to carry out 
detailed phenotype-genotype analyses, it is tempting to 
combine datasets in a meta-analysis. However, this has 
been hampered by a plethora of  different approaches 
to clinical classification of  the case population. Disease 
location is variously described as “any ileal” and “any 
colonic”, or “ileal and right colon” with “left colon and 
rectum”, without prior validation of  these systems[24,26,28]. 
Similarly, disease behavior, which clearly evolves with time, 
was modified from the Vienna classification in several 
studies, again making it difficult to combine datasets. 
Disease duration has often been omitted. There have been 
inconsistencies in defining disease location, including the 
inclusion or exclusion of  perianal abscess, combining ileal 
and ileocolonic locations without giving raw data on these 
locations individually and providing data on very specific 
subgroups, such as UC-like CD, where the number in this 
group (n = 56) is greater than the “colon-only” location as 
a whole (n = 29). More recent studies have concentrated 
on using the Vienna classification despite its known 
limitations, but have in some cases tried to address these 
limitations by carrying out supplemental analyses including 
investigation of  an association between NOD2/CARD15 
and stricturing disease independent of  penetrating disease 
and internal penetrating disease independent of  perianal 
disease.
In summary, studies thus far have provided us with 
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some important information on the strength of  the 
NOD2/CARD15 association with CD as a susceptibility 
gene but these have not been based on population-based 
cohorts. Population-based studies are awaited and may 
be best coordinated through an international effort using 
agreed upon methods of  case-control ascertainment, 
genotyping and clinical classification. Associations with 
ileal location have provided us with important clues to 
disease pathogenesis, including the role of  Paneth cells 
and defensins. However, extensive further work is required 
using much larger datasets that include other key variables, 
such as treatment received, to determine the mechanisms 
by which NOD2/CARD15 variants may increase the risk 
of  stricturing disease, and whether these variants are also 
implicated in the development of  internal penetrating 
disease. 
ResUlTs Of sTUDIes ON NOD2/CaRD15
TO DaTe
Multiple studies have now investigated the contribution 
of  variants in the LRR domain of  the NOD2/CARD15 
gene to development of  CD. This has been summarized 
in a recent meta-analysis. Individuals carrying only one 
high-risk allele had 2.39-fold (95% CI: 2.00-2.86) increased 
risk of  the disease, while those with 2 or more high risk 
alleles carried a 17.1-fold (10.7-27.2) increased risk of  CD 
compared to individuals without any high-risk alleles. The 
greatest relative risk was identified for the SNP13 variant 
(OR 3.76, 95% CI: 3.22-4.38 for one variant) but significant 
heterogeneity existed among studies (P = 0.01)[40].
For the purposes of  the rest of  this paper, we have 
selected 15 studies that each provide both genotype and 
(some) phenotype data on a minimum dataset of  200 CD 
cases[12,24-36,38]. We will discuss the evidence for associations 
between NOD2/CARD15 and key clinical variables 
including age at diagnosis, disease location and behavior, 
need for surgery and the presence of  granulomata. 
We have carried out further analyses on these studies 
as a combined dataset and as individual series, where 
sufficient clinical and genetic data are available in the 
original publication. We focus specifically on differences in 
phenotype and genotype among studies, and have carried 
out meta-analysis for NOD2 associations with disease 
location and behavior.
DIsease lOCaTION
Of  the 15 studies selected, 13 provide clearly interpretable 
data on disease location. Of  these, 10/13 support a 
significant association with ileal disease (L1)[12,25-27,31-34,36,38], 
while some also demonstrate an association with absence 
of  colonic location (L2)[24]. As indicated above, some 
studies have combined ileal (L1) with ileocolonic (L3) 
patients to investigate this association. This may be due to 
a lack of  power in subgroup analysis. Clinically, this may be 
inappropriate. There are limited data on the natural history 
of  ileocolonic disease compared with ileal disease but 
associations have been made between L3 and younger age 
at diagnosis and an increased risk of  surgical recurrence 
compared to other disease locations[43,44]. In addition, 
some patients with L3 may have their major disease 
burden in the colon, thus weakening the association 
with NOD2/CARD15 compared to pure ileal disease 
or L1. Once again, the interpretation of  results depends 
heavily on the clarity of  describing phenotypes, and in 
this case how the presence or absence of  ileal disease was 
determined, whether by endoscopy, histology, radiology or 
a combination of  these.
DIsease behavIOUR
Of  13 studies that provided data for the variable disease 
behaviour, 7 showed a significant association with 
stricturing behaviour[12,24,29,30,34,36,38]. Two studies show 
significant positive associations with both stricturing 
and penetrating disease behaviour[12,34], but one of  these 
excluded perianal penetrating disease from the analysis. 
If  included, this association with NOD2 variants is 
lost[12]. One study described a negative association with 
penetrating behaviour[26]. Penetrating disease is defined 
according to the Vienna classification in 8/13 studies and 
in another study it is defined as “internal penetrating” 
behaviour, separating it from perianal penetrating 
disease[12]. The rest of  the studies describe their own “in 
house” definition of  penetrating disease. Given the overlap 
between these forms of  disease behaviour and the length 
of  time some patients may take to develop “complex” 
CD, supplementary analyses seem necessary to clarify 
these observations. Specifically, stricturing CD will often 
occur in combination with penetrating disease, both being 
hallmarks of  transmural inflammation. One may therefore 
predict that NOD2/CARD15 should be associated with 
both complications. If  this is not the case, it may relate to 
a lack of  association of  NOD2/CARD15 with perianal 
penetrating disease that influences the relationship with 
penetrating disease overall, as suggested by Brant et al[12]. 
Alternatively, NOD2/CARD15 variants may promote the 
development of  fibrosis over fissuring ulceration. These 
questions clearly need to be addressed in future studies.
age aT DIagNOsIs
Five of  thirteen studies that looked for an association 
between NOD2/CARD15 and age of  d iagnos i s 
found a significant association with early onset of  the 
disease[12,24,26,32,38]. Of  these, 4 found association only 
for NOD2/CARD15 homozygotes and compound 
heterozygotes and 1 found association with these groups 
as well as with the frameshift variant alone. Importantly, 
these findings remained significant after multivariate 
analysis when important confounders such as disease 
location and stricturing behaviour were included. These 
data support the results of  previous linkage studies that 
demonstrated an association between IBD1 and earlier age 
at diagnosis[45]. They also support the concept of  pediatric 
CD being a “more genetic” disease, consistent with other 
polygenic disease models. 
OTheR ClINICal assOCIaTIONs
Eleven studies provided data on surgery for CD and 8 of  
Radford-Smith G et al . Phenotypes and NOD2 genotypes in CD                                                               7099
www.wjgnet.com
these provided NOD2/CARD15 genotype data on the 
“surgical” cohort. Two groups have identified an association 
between NOD2/CARD15 and increased risk of  surgery. 
Lakatos et al demonstrated this to have an independent 
effect on need for surgery after logistic regression (OR 
1.71, 95% CI: 1.13-2.62, P = 0.01) together with presence 
of  stricturing disease behaviour. This cohort had the 
largest complete dataset of  527 patients and provided 
the most comprehensive analysis of  NOD2/CARD15 
genotype-phenotype relation[38]. The second study showing 
this association also carried out similar statistical analysis, 
finding a higher risk for surgery with those carrying two 
variant alleles (OR 17.8, 95% CI: 4.9-64.3)[36].
fURTheR aNalysIs Of ClINICal
ChaRaCTeRIsTICs aND geNeTIC
assOCIaTIONs
Statistical methods
Differences in proportions among different studies were 
tested using simple c2 distribution obtained as the sum 
of  [(Observed – Expected)2/Expected] with (R-1)*(C-1) 
degrees of  freedom where R is the number of  rows 
(studies) and C is the number of  columns (locations, 
genotypes). The higher contribution to the c2 from 
different studies suggested a higher degree of  variation in 
the distribution of  reported location.
Meta-analysis was performed by calculating the 
odds ratio and confidence interval using the frequency 
distribution of  NOD2 variants and the variable of  
interest presented by studies involved in the analysis. 
Fixed analysis used an inverse variance method to 
calculate weight, and weighted average was calculated 
as a pooled estimate. Heterogeneity among studies was 
calculated using Cochran’s Q (sum of  squared difference 
between individual study effect and pooled effect across 
studies). Analysis was performed using Meta command in 
STATA 9[46].
Differences among studies
Ten studies gave clear data on numbers of  patients with 
pure ileal CD and their NOD2 variant frequencies. The 
majority of  studies had small numbers in this important 
subgroup of  CD (mean, 85 patients, range 23-136) with an 
overall NOD2 variant frequency of  41.1% (23.4%-53.6%). 
Comparisons between studies just failed to show a 
significant difference (P = 0.06). However, exclusion of  
one study from Finland, which is known to have lower 
NOD2 variant frequencies compared to the majority 
of  other European populations, demonstrated similar 
proportions in the majority of  these studies (P = 0.53). 
In contrast, a comparison of  disease location among 
12 studies that provided data on this variable as per 
the Vienna and Montreal systems, demonstrated highly 
significant differences (P < 0.0001). Unlike the genotype 
data for NOD2, exclusion of  any one study from this 
analysis did not influence heterogeneity. Proportions 
among s tud ies d id not appear to cor re la te wi th 
geographical region, but two groups emerged from the 
data; i.e., those with high rates of  ileal CD (40%-50%), 
and those with lower rates of  ileal disease (20%-30%). 
Does disease location for CD vary substantially among 
Caucasian populations? There are no population-based 
data to answer this question. Clearly, other factors may 
play a role, including rate of  familial disease, smoking, 
type of  center (medical or surgical bias), and methods of  
ascertainment. Interestingly, of  the four studies with high 
rates of  ileal disease, two had a high rate of  familial CD 
(0.47, 0.86), one had a relatively low rate (0.11), and the 
fourth did not include data on familiality. Similarly, figures 
for surgery did not show consistency within this subgroup, 
ranging from 0.33 to 0.67, and rate of  stricturing disease 
was surprisingly low (0.17-0.23). Alternatively, are there 
major differences in clinical assessment of  patients and 
a corresponding reduction in interobserver agreement 
among centers? Studies have recently indicated that this 
may be so for both CD behavior and location[47,48]. The 
NOD2 analysis given above indicates that, at least for 
NOD2 variant ileal CD, there are limited differences 
among populations. As indicated above at the outset of  
this review, clinical characterization of  CD, and IBD in 
general, remains a significant challenge.
meTa-aNalysIs Of NOD2 assOCIa-
TIONs wITh DIsease lOCaTION aND 
behavIOUR
Location
These analyses confirmed the strong association between 
NOD2 variants and pure ileal CD compared to pure 
colonic disease, which was used as the reference group 
(Figure 1). Similar results were obtained in comparing 
patients with ileocolonic disease and the reference group 
(Figure 2). Both meta analyses achieved significance (P 
< 0.0001), while there was no significant heterogeneity 
demonstrated between studies.
Behaviour
Nine studies provided adequate data for inclusion in these 
meta analyses, of  which four provided data on disease 
duration (range, 8.2-17.6 years). A strong association was 
confirmed between NOD2 variants and stricturing CD 
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Figure 1  Meta-analysis comparing odds of having a NOD2 variant (SNPs 8,12 
and/or 13) among Ileal versus Colonic CD patients in 10 studies. Pooled estimate = 
2.50 (95% CI 1.97-3.25), P < 0.0001), test of heterogeneity among studies, P = 0.49.
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(Figure 3) with inflammatory disease (non-stricturing, 
non-penetrating) as the reference group. Significant 
heterogeneity was detected among studies (P = 0.02) 
related to one “outlier”. Importantly, and not surprisingly, 
the other form of  complex disease behavior also showed 
significant association with NOD2 variants (Figure 4). 
This association is likely to be strengthened if  data were 
available for internal penetrating disease independent of  
perianal penetrating disease for all studies.
CONClUsION
The discovery of  NOD2 as the first susceptibility gene for 
CD has resulted in a leap forward in our understanding 
of  disease pathogenesis. It has also highlighted the 
heterogeneity of  the disease. NOD2 represents the “low-
lying fruit” of  CD genetics-other susceptibility genes for 
this disease and for ulcerative colitis may not carry the 
same relative risk. The phenotype-genotype studies carried 
out to date have provided us with the critical observations 
that link NOD2 variants to ileal location, and this has 
highlighted the role of  Paneth cells and antimicrobial 
peptides. However, there remain a number of  questions. 
All these studies have been drawn from special ist 
cohorts leaving no accurate figure for NOD2 population 
attributable risk. There is significant heterogeneity in 
phenotype among studies, raising concerns with respect 
to clinical characterization of  patients at different centers 
and thus the utility of  current classification systems and 
interobserver agreement in this field. Our meta-analysis 
has demonstrated a highly significant association between 
penetrating CD and NOD2 variants, and confirms the 
associations with stricturing behaviour and with both pure 
ileal and ileocolonic locations. These observations highlight 
the need for further clinical and genetic characterization 
of  phenotypes not associated with NOD2, including 
inflammatory CD, perianal (penetrating) disease, and pure 
colonic disease.
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